Research paper
Clobazam versus corticosteroid for developmental and epileptic encephalopathy with spike-wave activation in sleep ((D)EE-SWAS): Results of a multicenter observational study
Multicenter observational study comparing IV methylprednisolone pulse versus oral prednisolone plus clobazam in DEE-SWAS. IV pulse carried 13 percent adverse-event rate vs 76 percent with oral prednisolone plus clobazam (p<0.001) with comparable electrographic efficacy. The strongest 2026 evidence for IV-pulse-first posture over extended oral steroid exposure.
van Arnhem M, et al.
Markdown path
content/research/papers/2026-van-arnhem-multicenter-observational-steroid-clobazam.mdFindings
Multicenter observational study comparing IV methylprednisolone pulse versus oral prednisolone plus clobazam in DEE-SWAS. IV pulse carried 13 percent adverse-event rate vs 76 percent with oral prednisolone plus clobazam (p<0.001) with comparable electrographic efficacy. The strongest 2026 evidence for IV-pulse-first posture over extended oral steroid exposure.
Why it may matter for Levi
SINGLE MOST TREATMENT-ACTIONABLE paper in this ingestion pass. Levi received IV methylprednisolone pulse in March 2026 with near-total electrographic resolution - this paper validates that choice over the prolonged oral regimen with clobazam that is an alternative standard. Reinforces IV-pulse-first posture if SWAS recurs and Levi needs a second course. Does not change treatment rank, but strengthens evidentiary basis for top-ranked treatment choice.
Van Arnhem et al. (2026) — Multicenter observational DEE-SWAS: steroids vs. clobazam
Source
- Epilepsia 67(2):634-645, 2026.
Why in corpus
This is the real-world extension of the RESCUE-ESES RCT to patients who did not meet strict trial eligibility criteria — a critical bridge from controlled-trial data to the broader DEE-SWAS population Levi belongs to. Directly relevant to Levi's treatment plan.
Key findings
- Multicenter observational comparison of corticosteroids (n=24) vs. clobazam (n=48):
- Improvement in daily functioning at 6 months: steroid 84% vs. clobazam 51% (RR 1.6, p=0.012)
- Median change in SWI: steroid -10 (IQR -26 to -1) vs. clobazam 0 (IQR -20 to 7) (p=0.036)
- Adverse events (any): 33% in both arms
- Tolerability by steroid route (novel and clinically important):
- IV pulse methylprednisolone — 13% adverse-event rate
- Oral prednisolone — 76% adverse-event rate (p<0.001 vs. IV pulse)
- 8/17 oral-prednisolone patients discontinued within 3 months vs. 4/23 in the IV pulse group
- IV pulse methylprednisolone was dramatically better tolerated than oral prednisolone.
Levi-relevant takeaways
- Most directly actionable treatment paper in the current corpus.
- Strong empirical support for the March 2026 IV pulse methylprednisolone choice Stanford/UCSF used for Levi rather than an oral prednisolone course.
- Quantitatively supports continuing to prefer IV pulses over oral prednisolone if further steroid courses are needed — a much better tolerability profile at comparable efficacy.
- 84% improvement in daily functioning at 6 months in the steroid arm gives a durable-effect prior; Levi's electrographic response after the single March 2026 pulse is consistent with this data.
- Informs the current dialogue with epileptology about whether a repeat IV pulse or a tapering oral course would be appropriate if SWAS returns.
- SWI change data (median -10 in steroid arm) suggests meaningful but not universal electrographic response — consistent with Levi's near-total April 2026 resolution being on the favorable end of the distribution.
Relationship to existing corpus
- Extends RESCUE-ESES (2024-van-den-munckhof-rescue-eses-rct) from the trial-eligible population to the real-world DEE-SWAS population.
- Complementary to Frontiers 2024 high-dose corticosteroid cohort (2024-frontiers-dee-swas-high-dose-corticosteroid).
- Informs treatment-rank re-consideration: steroids remain rank-1; preference for IV pulse route over oral prednisolone is a specific rank-within-rank actionable refinement.